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 RESEARCH ARTICLE Open Access
C-reactive protein levels in patients at
cardiovascular risk: EURIKA study
Julian PJ Halcox1,2*, Carine Roy3, Florence Tubach3,4, José R Banegas5,6, Jean Dallongeville7, Guy De Backer8,
Eliseo Guallar9,10, Ogün Sazova11, Jesús Medina12, Joep Perk13, Philippe Gabriel Steg4,14,15,
Fernando Rodríguez-Artalejo5 and Claudio Borghi16
Abstract
Background: Elevated C-reactive protein (CRP) levels are associated with high cardiovascular risk, and might identify
patients who could benefit from more carefully adapted risk factor management. We have assessed the prevalence
of elevated CRP levels in patients with one or more traditional cardiovascular risk factors.
Methods: Data were analysed from the European Study on Cardiovascular Risk Prevention and Management in
Usual Daily Practice (EURIKA, ClinicalTrials.gov Identifier: NCT00882336), which included patients (aged ≥50 years)
from 12 European countries with at least one traditional cardiovascular risk factor but no history of cardiovascular
disease. Analysis was also carried out on the subset of patients without diabetes mellitus who were not receiving
statin therapy.
Results: In the overall population, CRP levels were positively correlated with body mass index and glycated
haemoglobin levels, and were negatively correlated with high-density lipoprotein cholesterol levels. CRP levels were
also higher in women, those at higher traditionally estimated cardiovascular risk and those with greater numbers of
metabolic syndrome markers. Among patients without diabetes mellitus who were not receiving statin therapy,
approximately 30% had CRP levels ≥3 mg/L, and approximately 50% had CRP levels ≥2 mg/L, including those at
intermediate levels of traditionally estimated cardiovascular risk.
Conclusions: CRP levels are elevated in a large proportion of patients with at least one cardiovascular risk factor,
without diabetes mellitus who are not receiving statin therapy, suggesting a higher level of cardiovascular risk than
predicted according to conventional risk estimation systems.
Trial registration: ClinicalTrials.gov Identifier: NCT00882336
Keywords: C-reactive protein, Cardiovascular disease, Epidemiology, Risk factors/global assessment
Background
Despite recent improvements in the management of
cardiovascular risk factors [1-4], cardiovascular disease
(CVD) remains the leading cause of death in Europe
[5,6]. Well-established risk factors for CVD include older
age, male sex, smoking, elevated cholesterol levels, hyper-
tension and diabetes mellitus [7]. Assessment of these
factors can be used to estimate patients’ global cardiovas-
cular risk. Two widely used cardiovascular risk estimation
systems are the Systematic Coronary Risk Evaluation
(SCORE), developed in Europe to evaluate 10-year risk of
cardiovascular mortality [8,9], and the Framingham Risk
Score (FRS), developed in the USA to estimate 10-year
risk of any cardiovascular event [10].
Global cardiovascular risk estimation is critical for
selecting appropriate management options in apparently
healthy, asymptomatic individuals according to current
clinical guidelines. For example, the European guidelines
on CVD prevention recommend prescription of blood
pressure medication or lipid-lowering drugs for patients
with hypertension or elevated serum cholesterol levels,
respectively, but only for those estimated to be at high
10-year cardiovascular risk (cardiovascular mortality of
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≥5% according to SCORE [7] or risk of major CVD event
of ≥20% according to the FRS). Exceptions are patients
who are already known to be at high cardiovascular risk
owing to having a history of CVD, diabetes mellitus or
chronic kidney disease, or having very high levels of single
risk factors [7].
In addition to traditional cardiovascular risk factors,
slight elevations of the inflammatory marker C-reactive
protein (CRP) may also indicate increased cardiovascular
risk [11-13]. Measurement of CRP levels may help to
identify patients who are at lower or greater cardiovas-
cular risk than is currently appreciated [13,14]. A recent
clinical trial of rosuvastatin in patients who have low
levels of low-density lipoprotein cholesterol (LDL-C)
(<130 mg/dL [<3.4 mmol/L]) but elevated levels of CRP
(≥2.0 mg/L) showed a 44% reduction in cardiovascular
event rates in the rosuvastatin treatment group com-
pared with placebo (the Justification for the Use of
Statins in Prevention: an Interventional Trial Evaluating
Rosuvastatin [JUPITER], ClinicalTrials.gov Identifier:
NCT00239681), translating to an absolute risk reduction
of 1.2%, and a number needed to treat of 95 for 2 years
[15]. The earlier Air Force/Texas Coronary Atheroscler-
osis Prevention Study (AFCAPS/TexCAPS) had shown
very low event rates and no evidence of beneficial effects
of statin treatment among lower-risk primary prevention
patients who had low levels of both LDL-C and CRP [16].
Elevated CRP levels may thus distinguish a group of pa-
tients who are at higher cardiovascular risk than predicted
according to conventional risk assessment tools, and who
might therefore derive a greater than expected benefit
from statin therapy.
The European Study on Cardiovascular Risk Preven-
tion and Management in Usual Daily Practice (EURIKA;
ClinicalTrials.gov Identifier: NCT00882336) was recently
conducted to assess the management of cardiovascular
risk factors in primary care in Europe [17-19]. We have
carried out a post hoc analysis of this study to assess the
prevalence of elevated CRP levels in patients with one or
more traditional cardiovascular risk factors, across a
range of levels of conventionally estimated global cardio-
vascular risk. In particular, patients were considered who
were estimated to be at intermediate levels of cardiovas-
cular risk according to SCORE and FRS, who did not
have diabetes mellitus (a marker of high cardiovascular
risk) and who were not already receiving statins (for
whom a treatment decision had already been made).
Methods
Study design and participants
The EURIKA study (ClinicalTrials.gov Identifier:
NCT00882336) was conducted in 12 European countries
(Austria, Belgium, France, Germany, Greece, Norway,
Russia, Spain, Sweden, Switzerland, Turkey and the UK),
selected to represent a broad spectrum of CVD risk across
Europe, as well as a variety of different healthcare systems.
Data collection started in May 2009 and ended in January
2010, with a 3-month data-collection period for each coun-
try. The study protocol was approved by the appropriate
clinical research ethics committees in each participating
country (lead ethics committee for host institution and
sponsor: Comité Ético de Investigación Clínica (CEIC) del
Hospital Universitario La Paz [Spain]), and all participating
patients provided signed informed consent.
The methods for the study have been reported else-
where [17]. Briefly, the study sample was selected in
a two-stage process that involved the random selec-
tion of both physicians and their patients [17,19]. In
the first stage, primary care practitioners (PCPs) and
specialists involved in CVD prevention (including car-
diologists, endocrinologists, and internal medicine
specialists) were randomly selected for invitation to partici-
pate using the OneKey database (Cegedim Dendrite,
Boulogne-Billancourt, France) [20]. In total, 809 physicians
(approximately 60 per country) agreed to participate in
EURIKA, 64% of whom were PCPs [19]. In the second
stage, participating physicians invited patients consecutively
visiting the clinic who met the selection criteria (age 50
years or older, free of CVD but having at least one major
cardiovascular risk factor; see ‘Patient Characteristics’) [18].
Approximately 600 patients were included per country,
with a final population size of 7641. For the present ana-
lysis, only patients for whom CRP measurements were
available were considered (n = 7565). All patients provided
signed informed consent forms. In each country, a random
sample of 10% of all study centres underwent a site visit for
data monitoring and audit to ensure data quality.
Patient characteristics
 Age 50 years or older.
 Free of clinical CVD (history of myocardial
infarction, stable or unstable angina, stroke or
transient ischaemic attack).
 At least one of the following cardiovascular risk
factors, assessed from the most recent data in the
clinical record, or using anthropometry for obesity.
○ Dyslipidaemia:
▪ LDL-C levels ≥4.1 mmol/L (≥160 mg/dL)
▪ high-density lipoprotein cholesterol (HDL-C)
levels <1.036 mmol/L (<40 mg/dL) for men
or <1.300 mmol/L (<50 mg/dL) for women
▪ triglyceride levels ≥1.7 mmol/L (≥150 mg/dL)
▪ receiving lipid-lowering medication.
○ Hypertension:
▪ systolic blood pressure (SBP) ≥140 mmHg
▪ diastolic blood pressure (DBP) ≥90 mmHg
▪ receiving antihypertensive medication.
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○ Smoking:
▪ current or former smoker, with >100 cigarettes
smoked in lifetime.
○ Diabetes mellitus:
▪ fasting plasma glucose ≥7.0 mmol/L
(126 mg/dL), or
▪ on antidiabetic medication (insulin or oral
medications).
○ Obesity:
▪ body mass index (BMI) ≥30 kg/m2, or
▪ waist circumference ≥102 cm in men or ≥88 cm
in women.
Assessment of cardiovascular disease risk factors
Information on participating patients was collected via
their medical records, clinical anamnesis, physical examin-
ation and a 12-hour fasting blood sample collected within
1 day of the outpatient consultation [17]. Blood samples
were sent to a central laboratory in Belgium for analysis
(the Bio Analytical Research Corporation NV, Ghent,
Belgium). CRP levels were measured by a high-sensitivity
immunoturbidimetry method (Roche P-Modular analyzer,
Roche, Germany), high-density lipoprotein cholesterol
(HDL-C) levels were measured by a modified enzymatic
method (Roche P-Modular analyzer, Roche, Germany),
total cholesterol levels were measured by the CHOD-PAP
method (Roche P-Modular analyzer, Roche, Germany) and
triglyceride levels were measured by the GPO-PAP method
(Roche P-Modular analyzer, Roche, Germany). LDL-C
levels were calculated by the Friedewald formula [21] and
glycated haemoglobin (HbA1c) levels were measured by
ion-exchange chromatography (Menarini 8160, Menarini
Diagnostics, Netherlands).
Metabolic syndrome markers
Metabolic syndrome markers that were considered were:
low HDL-C levels (<1.0 mmol/L in men or <1.3 mmol/L
in women), high triglyceride levels (≥1.7 mmol/L), high
HbA1c levels (≥6%), large waist circumference (cut-off
dependent on ethnicity [European Caucasian, Sub-
Saharan, Middle East/North African and Afro-American:
males ≥94 cm and females ≥80 cm; Asian, South American
and Caribbean: males ≥90 cm and females ≥80 cm; Native
American: males ≥102 cm and females ≥88 cm], in line
with clinical guidelines [22]) and high blood pressure
(systolic blood pressure ≥130 mmHg and/or diastolic
blood pressure ≥85 mmHg, or taking antihypertensive
medication). Global cardiovascular risk was estimated
according to the SCORE and FRS systems [8,10].
Statistical analysis
Statistical analyses were carried out using SAS (V9.2,
SAS Institute Inc., Cary, NC, USA). Associations be-
tween demographic factors and log CRP values were
assessed using Pearson correlation coefficients for con-
tinuous variables, analysis of variance for categorical
values in three or more categories, and Student’s t-tests
for binary data. A multivariate linear regression model
was developed, adjusted for all factors associated with
log CRP values in univariate analysis. Statistical signifi-
cance was defined as two-sided P < 0.05.
Results
Demographic and baseline characteristics
The demographic and baseline characteristics for the
overall study population, the subgroup of patients with-
out diabetes mellitus who were not receiving statin ther-
apy, and the subgroup of those estimated to be at an
intermediate risk (SCORE: 10-year risk of death ≥1%
to <5% without diabetes mellitus) who were not receiv-
ing statin therapy are shown in Table 1.
Overall, the mean age of patients was 63.2 years, and
approximately 50% were women. Almost 60% of patients
had dyslipidaemia, more than 70% had hypertension, just
over 25% had diabetes mellitus and more than 40% were
obese (mean body mass index [BMI] was approximately
30 kg/m2). The characteristics of patients in the sub-
group without diabetes mellitus who were not receiving
statin therapy were similar to those of the overall popu-
lation, except for a lower proportion of patients with
dyslipidaemia. Mean levels of total cholesterol, LDL-C,
HDL-C and triglycerides in the overall population and in
patients without diabetes mellitus who were not receiv-
ing statin treatment were similar. The characteristics of
patients in the subgroup of those at intermediate risk
who were not receiving statin therapy were also largely
similar to those of the overall population, except for a
lower proportion of individuals with dyslipidaemia.
Factors correlating with CRP levels
The mean CRP level in the overall population was
4.2 mg/L, and this was similar to levels seen in the sub-
group of patients without diabetes mellitus who were not
receiving statin therapy, and in the subgroup of those at
intermediate risk and not receiving statin therapy (Table 1).
The distribution of log CRP levels in the overall patient
population is shown in Figure 1. The distribution of CRP
values is skewed to the right; hence, associations between
demographic factors and CRP levels were assessed using
the logarithm of CRP values. After univariate analysis, a
multivariate linear regression model was developed, ad-
justed for the values of all factors found to be associated
with log CRP levels in univariate analysis. In multivariate
analysis, CRP levels were significantly (P < 0.05) positively
associated with BMI and HbA1c levels (although these as-
sociations were of a small magnitude), and were negatively
associated with HDL-C levels (Table 2). CRP levels were
also significantly higher in: women than in men; patients
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at an estimated high global cardiovascular risk than in
those at an estimated low global cardiovascular risk;
and those with several metabolic syndrome markers than
in those with no metabolic syndrome markers. No signifi-
cant association was found between CRP levels and age,
although the study included only individuals aged over
50 years.
In the overall population, patients with higher levels of
CRP were more likely to have a greater number of meta-
bolic syndrome markers than those with lower levels
of CRP (Figure 2). A total of 34.3% of patients with
CRP levels ≥3 mg/L had 4 or 5 metabolic syndrome
markers, compared with 14.5% of patients with CRP
levels <1 mg/L. Furthermore, only 8.4% of patients with
Table 1 Baseline characteristics in the overall population, and in patients without diabetes mellitus and not receiving statins
Overall Patients without diabetes mellitus who
were not receiving statin treatment
Patients at intermediate riska and
not receiving statin treatment
(N = 7565) (n = 3434) (n = 1573)
Age, years 63.2 (9.0) 61.9 (9.2) 58.2 (5.6)
Women, n (%) 3903 (51.6) 1872 (54.5) 909 (57.8)
Dyslipidaemia, n (%) 4372 (57.8) 879 (25.6) 439 (27.9)
Total cholesterol, mmol/L 5.5 (1.1) 5.8 (1.0) 5.8 (1.0)
LDL-C, mmol/L 3.2 (1.0) 3.6 (0.9) 3.6 (0.9)
HDL-C, mmol/L 1.4 (0.4) 1.5 (0.4) 1.5 (0.4)
Triglycerides, mmol/L 1.8 (1.3) 1.7 (1.2) 1.7 (1.0)
Hypertension, n (%) 5496 (72.7) 2471 (72.0) 1076 (68.4)
SBP, mmHg 135.0 (16.6) 135.5 (16.8) 132.4 (14.6)
DBP, mmHg 80.9 (9.9) 82.1 (10.1) 82.0 (9.6)
Diabetes mellitus, n (%) 2027 (26.8) 0 (0.0) 0 (0.0)
BMI, kg/m2 28.9 (5.4) 28.4 (5.4) 28.8 (5.5)
Obese, n (%) 3288 (43.5) 1357 (39.5) 677 (43.0)
Current smoker, n (%)b 1594 (21.3) 862 (25.5) 423 (26.9)
CRP, mg/L 4.2 (8.7) 4.3 (8.4) 4.2 (7.5)
Data are mean (standard deviation) unless otherwise indicated.
aIntermediate risk defined as a SCORE estimate of ≥1% to <5%.
bPercentages were calculated for the total number of patients for whom data were available.
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CRP levels ≥3 mg/L had 0 or 1 metabolic syndrome
markers, compared with 25.8% of patients with CRP
levels <1 mg/L. This trend was also apparent when
CRP levels were considered in categories of <2 mg/L
and ≥2 mg/L (Additional file 1: Figure S1). Similarly, CRP
levels were progressively higher in patients with greater
numbers of metabolic syndrome markers (Additional
file 2: Figure S2). The proportion of patients in the over-
all population and with CRP levels <1 mg/L, 1–3 mg/L
and ≥3 mg/L with each metabolic syndrome marker are
shown in Table 3. The prevalence of each metabolic syn-
drome marker increases with increasing CRP levels.
Elevated CRP levels according to global cardiovascular
risk category
Of patients without diabetes mellitus who were not re-
ceiving statin treatment, more than one-third (range:
34.0 to 41.3%) of patients in each risk category, whether
classified according to either SCORE or FRS, had CRP
levels ≥3 mg/L (Figure 3). Approximately 40% of all pa-
tients had CRP levels in the range of 1 to 3 mg/L, and ap-
proximately 20% had CRP levels <1 mg/L. The proportion
of patients with CRP levels <2 mg/L and ≥2 mg/L was also
assessed (Additional file 3: Figure S3). Approximately half
of all patients had CRP levels ≥2 mg/L, regardless of esti-
mated global cardiovascular risk. Specifically, among those
at an estimated intermediate (1 to <5%) 10-year risk of car-
diovascular death according to SCORE, 38.2% had CRP
levels ≥3 mg/L, and 54.1% had CRP levels ≥2 mg/L.
Among those at an estimated intermediate (10 to 20%)
10-year risk of any cardiovascular event according to
FRS, 34.0% had CRP levels ≥3 mg/L and 49.2% had
CRP levels ≥2 mg/L.
Discussion
In this analysis of data from a large, multinational
European study of the control of cardiovascular risk
factors, we have shown that, among patients aged
50 years or older with at least one traditional cardiovas-
cular risk factor who do not have diabetes mellitus and
are not receiving statin treatment, more than one-third
have CRP levels ≥3 mg/L, and approximately half have
CRP levels ≥2 mg/L. This is the case irrespective of the glo-
bal cardiovascular risk score, estimated using the two most
widely used conventional risk estimation systems (SCORE
and FRS). In particular, 34.0 to 38.2% of patients without
diabetes mellitus who were not receiving statin therapy,
and at an estimated intermediate 10-year cardiovascular
Table 2 Association of log-CRP levels with demographic
and clinical characteristics: multivariate analysis in the
overall population
Linear regression
coefficient (SE)
P value
Sex
Male – –
Female 0.23 (0.03) <0.0001
Cardiovascular risk
Lowa – –
Intermediateb 0.16 (0.05) 0.0005
Highc 0.21 (0.05) <0.0001
HDL-C, mmol/L −0.24 (0.04) <0.0001
BMI, kg/m2 0.05 (0.00) <0.0001
HbA1c,% 0.06 (0.01) <0.0001
Number of metabolic syndrome
markers present
0 – –
1 0.02 (0.08) 0.8226
2 0.07 (0.08) 0.3584
3 0.14 (0.08) 0.0807
4 0.20 (0.09) 0.0197
5 0.16 (0.10) 0.0992
Values were adjusted for factors found to be associated with log CRP levels in
univariate analysis, including country, sex, systolic blood pressure, HDL-C
levels, BMI, HbA1c, number of metabolic syndrome markers and cardiovascular
risk category.
aSCORE <1%, without diabetes mellitus.
bSCORE ≥1% to <5%, without diabetes mellitus.
cSCORE ≥5%, or with diabetes mellitus.
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risk according to SCORE or FRS, had CRP levels ≥3 mg/L,
and 49.2 to 54.1% had CRP levels ≥2 mg/L. Elevated base-
line CRP levels are associated with increased cardiovascular
risk [11,12]; hence, it may be more appropriate to consider
classifying such patients in the high-risk category, for
whom pharmaceutical intervention for risk factor manage-
ment may be appropriate [7,23]. The high prevalence of
elevated CRP levels in patients considered to be at inter-
mediate risk indicates that assessment of CRP levels in
these individuals is likely to identify a considerable number
of patients who are at higher risk than would be expected
on the basis of their conventional risk factors alone.
Patients with diabetes mellitus were excluded from the
analysis because they were already considered to be at high
risk [7], and patients receiving statins were excluded be-
cause a positive treatment decision had already been made.
Thus, almost a quarter (23.3%) of the EURIKA study
patients without diabetes mellitus and not already taking a
statin were found to be at intermediate risk by SCORE and
had CRP levels ≥2 mg/L (17% had CRP levels ≥3 mg/L).
These patients represent approximately 10% (and 8%
respectively) of the entire EURIKA study cohort.
Data from the JUPITER study support the hypothesis
that measurement of CRP levels could be used to iden-
tify individuals who are likely to benefit from statin ther-
apy, although this approach is not currently endorsed by
European guidelines. In this study, ‘high-risk’ cardiovas-
cular event rates were observed among patients receiv-
ing placebo treatment with CRP levels ≥2 mg/L, but
considered to be at intermediate cardiovascular risk ac-
cording to SCORE and FRS [15]. Statin treatment in this
population resulted in a greater absolute risk reduction
Table 3 Metabolic syndrome markers, overall and according to CRP levels
Overall CRP <1 mg/L CRP 1 to 3 mg/L CRP ≥3 mg/L
(N = 7565) (n = 1739) (n = 3104) (n = 2722)
n (%) n (%) n (%) n (%)
Low HDL-Ca 1690 (22.3) 240 (13.8) 612 (19.7) 838 (30.8)
High triglyceridesb 3046 (40.3) 514 (29.6) 1237 (39.9) 1295 (47.6)
High HbA1c
c 2781 (36.8) 493 (28.3) 1092 (35.2) 1196 (43.9)
Large waist circumferenced 6150 (81.3) 1223 (70.3) 2571 (82.8) 2356 (86.6)
High blood pressuree 6436 (85.1) 1390 (79.9) 2628 (84.7) 2418 (88.8)
a<1.0 mmol/L in men or <1.3 mmol/L in women.
b≥1.7 mmol/L.
c≥6%.
dCut-off dependent on ethnicity (European Caucasian, Sub-Saharan, Middle East/North African and Afro-American: males ≥94 cm and females ≥80 cm; Asian,
South American and Caribbean: males ≥90 cm and females ≥80 cm; Native American: males ≥102 cm and females ≥88 cm), in line with clinical guidelines [22]).
eSystolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg, or taking antihypertensive medication.
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than would have been predicted on the basis of reduc-
tions in levels of LDL-C alone [15,24]. These data from
the EURIKA study show that such individuals are very
common in primary care in Europe. We have also shown
that, in the overall population, CRP levels are positively
associated with BMI, HbA1c levels and the number of
components of the metabolic syndrome present, and are
negatively associated with HDL-C levels. We observed
that CRP levels were higher in women than in men, and
higher in those predicted to be at high cardiovascular
risk than in those predicted to be at low cardiovascular
risk according to SCORE.
Although there is considerable and consistent evidence
for an association between CRP levels and cardiovascu-
lar risk, the use of CRP measurement in cardiovascular
risk assessment remains controversial [25,26]. A meta-
analysis published in 2004 of 22 population-based pro-
spective studies, including a total of 7068 incident cases
of coronary heart disease, found an adjusted odds ratio
for the incidence of coronary heart disease of 1.6 (95%
confidence interval 1.5 to 1.7) in patients with baseline
CRP levels in the top third of the population analysed
(approximately ≥2.4 mg/L), compared with patients with
baseline CRP levels in the bottom third (approximately
1.0 mg/L) [11]. However, as our data support, CRP levels
are positively associated with several established cardio-
vascular risk factors, including high blood pressure,
atherogenic dyslipidaemia, high BMI, diabetes mellitus,
metabolic syndrome and smoking, and are low in indi-
viduals with protective factors, including high levels of
physical activity, high HDL-C and apolipoprotein A1
levels, and consumption of fruits and vegetables [27-32].
Incomplete adjustment for confounding factors in multi-
variate analysis may therefore lead to an overestimation
of the strength of association between CRP levels and
risk. In support of this, as the number of established
cardiovascular risk factors adjusted for in multivariate
analysis models increases, the correlation of CRP levels
with cardiovascular risk decreases [33]. Although our
multivariate analysis model was adjusted for all factors
found to be associated with CRP levels in univariate
analysis, it is possible that the results could still be con-
founded by CVD risk factors that were not assessed
and which are associated with CRP levels, such as diet-
ary habits, levels of physical activity, and low-grade
infection such as periodontal disease. The weak inde-
pendence of CRP levels as a predictor of cardiovascular
risk makes it unlikely that increased CRP is a major
causal factor for CVD. Moreover, there is no association
between cardiovascular event rates and genetic factors
that raise CRP levels but have no effect on other cardio-
vascular risk factors [33]. Such an association would be
expected if elevated CRP levels are genuinely causally
linked to CVD.
Additionally, a narrative review published in 2006
questioned the value of the universal use of CRP mea-
surements in global cardiovascular risk estimation, on
the basis that a very high adjusted odds ratio would be re-
quired to provide a moderate improvement in the accur-
acy of current risk-estimation systems [25]. However, this
review did acknowledge that elevated CRP levels may
help to distinguish patients who are currently classified
as being at intermediate risk using conventional estima-
tion systems, but who may have event rates comparable
to those in high estimated risk groups [25,34]. It should
also be noted that CRP levels differ considerably between
individuals and may fluctuate over time within indi-
viduals, so developing a universal system for assessing car-
diovascular risk based on single measurements and cut-off
CRP values may be challenging [35-40]. However, their
variability appears no greater than that of blood pressure
and lipid levels. After the initial measurement of CRP
levels, repeat measurements can be made at follow-up
visits to the PCP.
JUPITER reported that patients with low levels of
LDL-C but high levels of CRP benefitted from statin
therapy, while the earlier AFCAPS/TexCAPS study
found that patients with low levels of both LDL-C and
CRP did not [15,16]. In contrast to both of these find-
ings, an analysis of the Heart Protection Study showed
that patients benefitted from statin therapy regardless of
either their LDL-C or CRP levels [41]. Furthermore, an
analysis of data from the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT) showed that CRP levels did
not predict the efficacy of statin treatment in patients
with LDL-C levels ≤250 mg/dL (6.5 mmol/L) [42]. How-
ever, the majority of patients recruited into these studies
would already be considered to be at high cardiovascular
risk on the basis of established CVD, diabetes mellitus,
or severe or complicated hypertension. These studies are
therefore less relevant to the main question considered
here, specifically regarding how we might improve the
identification of individuals from lower-risk groups who
might derive greater than otherwise expected reductions
in their absolute CVD risk with more intensive risk fac-
tor treatment. It should be noted that the AFCAPS/
TexCAPS study used lovastatin, a less potent agent than
rosuvastatin, which was used in the JUPITER study
[15,16]. It is therefore possible that the intensity of treat-
ment in the AFCAPS/TexCAPS study was not sufficient
for an outcome benefit to be detected in the lower-risk
subgroup of patients with low levels of both LDL-C and
CRP.
Our study has the strength of centralized assessment
of a large sample of patients from multiple countries ac-
cording to standardized procedures. The participation
acceptance rate among physicians was low (3.1 to 22.8%
across all countries), but the random selection of patients
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and a relatively high patient acceptance rate of 62.1%
within the participating physicians’ practices is likely to
have reduced patient selection bias. It should also be noted
that, because the data-collection period for each country
was only 3 months, it is possible that frequent healthcare
service users were over-represented in the study cohort.
This may bias the patient population towards the inclusion
of less healthy patients, who could have higher CRP levels
than healthier individuals.
Conclusions
In conclusion, we have shown that a large proportion of
patients aged over 50 years and with at least one trad-
itional cardiovascular risk factor but no previous history
of CVD, who do not have diabetes mellitus and who are
not currently being treated with statins, have elevated
levels of CRP. This is true regardless of these patients’
levels of cardiovascular risk, estimated according to con-
ventional risk-estimation systems. This is of particular
importance for patients currently classified as being at
intermediate risk, for whom elevated CRP levels could
indicate that they are at higher risk than expected and
likely to derive a greater absolute reduction in CVD event
rates if pharmacological treatment for risk factor manage-
ment were provided [7]. For these patients, evaluation of
CRP levels is therefore likely to offer a meaningful clinical
benefit.
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